Jump to content

EHP-102

Add links
From Wikipedia, the free encyclopedia

EHP-102
Clinical data
Other namesEHP102; VCE-003.2; VCE003.2
Routes of
administration		Oral[1]
Drug classCannabinoid CB2 receptor agonist; PPARγ agonist
Identifiers
  • 3-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(ethylamino)-4-hydroxy-6-pentylcyclohexa-3,5-diene-1,2-dione
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC23H35NO3
Molar mass373.537 g·mol−1
3D model (JSmol)
  • CCCCCC1=C(C(=C(C(=O)C1=O)C/C=C(\C)/CCC=C(C)C)O)NCC
  • InChI=1S/C23H35NO3/c1-6-8-9-13-18-20(24-7-2)21(25)19(23(27)22(18)26)15-14-17(5)12-10-11-16(3)4/h11,14,24-25H,6-10,12-13,15H2,1-5H3/b17-14+
  • Key:MRCQPMQBCKEOCU-SAPNQHFASA-N

EHP-102, also known as VCE-003.2, is a cannabinoid CB2 receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease.[1][2][3][4] It is taken orally.[1] The drug is a derivative of cannabigerol (CBG).[4] It is under development by Emerald Health Sciences.[1][2][3] As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.[1][2][3]

See also

[edit]

References

[edit]
  1. ^ a b c d e "EHP 102". AdisInsight. 28 February 2024. Retrieved 2 June 2026.
  2. ^ a b c "Delving into the Latest Updates on EHP-102 with Synapse". Synapse. 24 May 2025. Retrieved 2 June 2026.
  3. ^ a b c Shaffer C (1 March 2020). "Medical Cannabis Pioneers Stake Their Claims: Across the medical cannabis frontier, natural cannabinoids, synthetic analogues, rationally designed ligands, and prodrugs are being developed". Genetic Engineering & Biotechnology News. 40 (3): 52–55. doi:10.1089/gen.40.03.14. ISSN 1935-472X.
  4. ^ a b Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, et al. (July 2016). "VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease". Scientific Reports. 6 29789. doi:10.1038/srep29789. PMC 4949444. PMID 27430371.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=EHP-102&oldid=1357362207"